149 min listen
#22 - Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins
#22 - Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins
ratings:
Length:
64 minutes
Released:
Oct 17, 2018
Format:
Podcast episode
Description
In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter's most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part III, Peter and Tom dig into HDL, why "reverse cholesterol transport" is a lot more nuanced than what most of us are taught, lipid transport, apolipoproteins, and more. In addition, this episode highlights the complexity of HDL and a discussion about the CETP inhibitor trials. We discuss: Reverse cholesterol transport [1:40]; Lipid transportation, apolipoproteins, VLDL, IDL, and LDL particles [11:00]; Remnant lipoproteins and apoC-III [16:45]; Particles having sex: lipid exchange [28:00]; Cholesteryl Ester Transfer Protein (CETP) and CETP inhibitors [40:45]; 2006 CETP inhibitor trial: torcetrapib (Pfizer) [54:45]; 2012 CETP inhibitor trial: dalcetrapib (Hoffmann–La Roche) [56:15]; 2017 CETP inhibitor trials: evacetrapib (Eli Lilly) and anacetrapib (Merck) [58:00]; and More. Learn more at www.PeterAttiaMD.com Connect with Peter on Facebook | Twitter | Instagram.
Released:
Oct 17, 2018
Format:
Podcast episode
More Episodes from The Peter Attia Drive
Special episode with Dax Shepard: F1 and the 30th anniversary of Ayrton Senna’s death: This is a special episode of The Drive with Peter’s friend and fellow car enthusiast Dax Shepard. In this podcast, which commemorates the 30th anniversary of the death of Brazilian Formula One legend Ayrton Senna, Dax sits down with Peter to better... by The Peter Attia Drive